

CareKinesis Clinical Advisory Panel

The Disney Gland Floridian Resort and Spa

September 20-21, 2018

AGENDA

Thursday, September 20th

New Medical Directors Pharmacodynamics and Pharmacokinetics Orientation

Room: Salon 2

1:00 pm Buffet Lunch Begins

3:00 pm Refreshments
Introductions
History of the CareKinesis Clinical Advisory Panel
Richard Schamp, MD, CMO Tabula Rasa HealthCare
Calvin Knowlton, PhD, CEO Tabula Rasa HealthCare

3:15 p.m. **Anticholinergic, Sedative Burden, and PGx (1.5 CEUs)**
Kevin Bain, PharmD, MPH, SrVP, Research & Development

- Explain the risks associated with anticholinergic and sedative medication use in older adults
- Compare and contrast methods for quantifying anticholinergic and sedative burden,
- Describe how genetic variants may affect drug pharmacokinetics and pharmacodynamics for a series of drugs

4:45 p.m. Break

5:00 p.m. **Competitive Inhibition and LQTS: Managing Accumulative, Multi-Drug Interactions (1.5 CEUs)**
Lauren Steffen, PharmD, BCGP, Director, Education & Training

- Explain basic principles as it pertains to bioavailability, drug metabolism and competitive inhibition.
- Evaluate therapeutic effects related to enzyme substrates, inhibitors and inducers.
- Calculate dose changes required under conditions of competitive inhibition.
- Apply basic electrophysiological concepts to the understanding of underlying mechanisms of QT prolongation and Torsade de Pointes.
- Conduct a review of the predisposing factors to drug-induced Long QT Syndrome and apply these concepts to management of individual cases.

General Discussion & Feedback
Richard Schamp, MD, CMO Tabula Rasa HealthCare
Calvin Knowlton, PhD, CEO Tabula Rasa HealthCare

6:30 p.m. Break

All Medical Directors and Guests

Whitehall Room & Patio (weather permitting)

Room: Salon 8

7:00 p.m. Refreshments

CareKinesis Clinical Advisory Panel

The Disney Gland Floridian Resort and Spa

September 20-21, 2018

AGENDA

7:30 p.m. Introductions and Dinner

8:15 p.m. **Enhanced Medication Therapy Management (30 minutes; 0.5 CEU)**

Calvin Knowlton, PhD, CEO Tabula Rasa HealthCare

- Recognize the components of the model that characterize EMTM compared to traditional MTM
- Identify benefits of EMTM in the patient care process
- Describe the impact EMTM, including use of additional technology, can have on patient outcomes

General Discussion and Feedback

9:30 p.m. Adjourn

Friday, September 21st

Clinical Advisory Panel Meeting

Room: Salon 2 & 3

7:00 a.m. Breakfast buffet will be available in Room: **St. Augustine A**

8:30 a.m. New developments at CareKinesis

Calvin Knowlton, PhD, CEO Tabula Rasa HealthCare

9:00 a.m. **Topic 1: Risk Stratification Models (1 CEU)**

Kevin Bain, PharmD, MPH, SrVP, Research & Development

- Define the concepts of risk stratification
- Discuss the advantages of utilizing risk stratification models
- Distinguish how risk stratification models are used as predictive tools
- Compare different risk scoring systems currently utilized in the healthcare system
- Provide examples of “success stories” from PACE

Feedback & Discussion

Topic 2: Fundamentals of Treating Pain in Geriatrics (1 CEU)

Kevin Bain, PharmD, MPH, SrVP, Research & Development

David Wensel, DO, Medical Director, Midland Care

- Discuss the use of “alternative” pain management strategies
- Discuss evidence-based results for use of non-opioid analgesics, anesthetics and nerve blockers, and physical therapies
- Describe drug interactions between opioids and non-opioids
- Explain the role of PACE organizations, including the interdisciplinary care team, in pain management

CareKinesis Clinical Advisory Panel

The Disney Gland Floridian Resort and Spa

September 20-21, 2018

AGENDA

Feedback & Discussion

11:00 a.m. Break and Networking

11:30 a.m. Working lunch

Topic 3: Geriatric Pharmacotherapy Mini-Series Part 1: Anticoagulation and Dual Anti-Platelet Therapy (DAPT) for Stroke (1.5 CEU)

Hiren Shah, PharmD, BCGP Clinical Pharmacist

Birju Patel, PharmD, BCGP, Clinical Pharmacist

George W. "Mike" Brett, MD, Senior VP for Consulting Services; Chief Medical Officer, Facilitator

- Identify current clinical practice guidelines related to anticoagulation and dual-antiplatelet therapy for stroke
- Recognize scenarios that may not be clearly described in clinical practice guidelines and the scientific evidence that can be used to guide management of anticoagulation and dual anti-platelet therapy for stroke
- Describe appropriate monitoring and follow-up for scenarios that may not be clearly delineated in clinical practice guidelines related to anticoagulation and dual anti-platelet therapy for stroke
- Discuss successes or challenges providers have experienced with respect to anticoagulation and dual-antiplatelet therapy for stroke

Topic 4: Geriatric Pharmacotherapy Mini-Series Part 2: Tapering Antipsychotics and Opioids (1 CEU)

Robert Alesiani, PharmD, BCGP Chief Pharmacotherapy Officer

George W. "Mike" Brett, MD, Senior VP for Consulting Services; Chief Medical Officer, Facilitator

- Identify current clinical practice guidelines related to tapering antipsychotics and opioids
- Recognize scenarios that may not be clearly described in clinical practice guidelines and the scientific evidence that can be used to guide tapering antipsychotics and opioids
- Describe appropriate monitoring and follow-up for scenarios that may not be clearly delineated in clinical practice guidelines related to tapering antipsychotics and opioids
- Discuss successes or challenges providers have experienced with respect to tapering antipsychotics and opioids

2:00 p.m. Good and Welfare